Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2017 | Rituximab vs. standard chemotherapy: which treatment benefits B-cell ALL patients more?

David Marks • 6 Nov 2017
NCRI 2017
Acute Lymphoblastic Leukemia Leukemia Antibodies Rituximab
UKALL14

Can patients with B-cell acute lymphoblastic leukemia (ALL) benefit more from using rituximab as part of their treatment compared to using standard chemotherapy alone? This is one question that Prof. David Marks, MBBS, PhD, FRACP, FRCPath, of University Hospitals Bristol NHS Foundation Trust, Bristol, UK, has investigated during the UKALL14 trial (NCT01085617). Speaking at the 2017 National Cancer Research Institute (NCRI) Conference in Liverpool, UK, Prof. Marks briefly talks about the primary endpoints of the trial and expresses his interest in finding out the results gathered.

More from David Marks

The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
1:56
The feasibility of chemotherapy-free regimens without allogeneic transplantation in MRD- Ph+ALL
David Marks • 24 Apr 2023
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
3:36
UKALL14: rituximab dose & reduced intensity transplant in B-ALL & nelarabine consolidation in T-ALL
David Marks • 24 Apr 2023
The importance of MRD assessment before alloSCT in ALL
1:37
The importance of MRD assessment before alloSCT in ALL
David Marks • 24 Apr 2023
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
3:24
Improving risk stratification in ALL with risk scores & genomic studies to personalize therapy
David Marks • 24 May 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals